Latest Us Market News

DroneShield has landed a $24.9 million contract with the US Department of War’s Joint Interagency Task Force 401 to supply mobile and fixed counter-drone solutions, reinforcing its foothold in the US defence market.

Pure Resources has appointed retired US Navy Vice Admiral Jeff Trussler to its advisory board, aiming to fast-track US government funding and integration of its advanced materials into defence supply chains.

QuickFee Limited has reported a robust 77% increase in Australian originations for Q4 FY26 to-date, driven by strong Fee Funding and Disbursement Funding growth. The company boosted its Australian credit facility by A$15 million, signalling confidence in its low-risk lending model, while US operations focus on reseller channel expansion amid a product embedding delay.

Nova Minerals shareholders and Nasdaq warrantholders overwhelmingly approved schemes to restructure the company under a new US holding entity, pending final court approval.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

ArborGen Holdings delivered its strongest revenue in five years with $68.2 million, driven by a 14% surge in Brazil and an 8% rise in adjusted EBITDA despite US market headwinds. The company’s focus on advanced genetics and operational efficiency underpins a confident FY27 outlook.

4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.

Bubs Australia expects FY26 revenue between $105 million and $115 million, with underlying EBITDA forecast at $4 million to $8 million despite external challenges including regulatory delays and increased air freight costs.

Volt Group reported an 8% revenue decline in FY25 amid strategic shifts but is poised for growth with the 4D Delta acquisition driving a 150% revenue surge in Q1 FY26.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Australian Vintage Limited has locked in a $128 million refinancing deal extending to 2029 and reported a significant cash flow turnaround in FY26, driven by innovation and strategic acquisitions.

HighCom Limited has locked in a $4.5 million loan facility with Commonwealth Bank, replacing its US debt and complementing a recent $7.8 million capital raise to fuel working capital and sales expansion.